Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Risk of selecting K65R in antiretroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir.

AIDS (London, England) - 18 Nov 2005

Sheldon Julie A, Corral Angélica, Rodés Berta, Mauss Stefan, Rockstroh Juergen, Berger Florian, Schwarze-Zander Carolynne, Soriano Vincent

Abstract excerpt

Seven antiretroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir for longer than 6 months were assessed. Using bulk population sequencing and a sensitive limiting dilution analysis, the selection of K65R or other resistance mutations did not occur in HIV, suggesting that adefovir can be confidently used as hepatitis B virus (HBV) therapy in HIV/HBV-co-infected patients who do not...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenine
Share to Antiviral Agents

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to DNA, Viral

Share to Genes, Viral

Share to Hepatitis B, Chronic

Share to Hepatitis B e Antigens

Share to HIV Infections

Share to Organophosphonates

Source

Identifiers

PMID: 16260913
DOI: 10.1097/01.aids.0000189563.79976.05

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Risk of selecting K65R in antiretroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir.PMID 16260913Read ↗

K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine.Semantic proximity Read ↗

Dynamics of lamivudine-resistant hepatitis B virus during adefovir monotherapy versus lamivudine plus adefovir combination therapy.Semantic proximity Read ↗

HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir.Semantic proximity Read ↗

Hepatitis B virus resistance to adefovir in a nucleotide naive patient with chronic hepatitis B virus infection.Semantic proximity Read ↗

Characterization of the dynamics of hepatitis B virus resistance to adefovir by ultra-deep pyrosequencing.Semantic proximity Read ↗

Low-level K65R mutation in HIV-1 reverse transcriptase of treatment-experienced patients exposed to abacavir or didanosine.Semantic proximity Read ↗

Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patientSemantic proximity Read ↗

Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B.Semantic proximity Read ↗

Selection of K65R mutation in HIV-2-infected patients receiving tenofovir-containing regimen.Semantic proximity Read ↗

Impact of a treatment including tenofovir plus didanosine on the selection of the 65R mutation in highly drug-experienced HIV-infected patients.Semantic proximity Read ↗

Severe hepatitis and prolonged hepatitis B virus-specific CD8 T-cell response after selection of hepatitis B virus YMDD variant in an HIV/hepatitis B virus-co-infected patient.Semantic proximity Read ↗

Human immunodeficiency virus type 1 reverse transcriptase mutation selection during in vitro exposure to tenofovir alone or combined with abacavir or lamivudine.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.